Registered title, quoted from ClinicalTrials.gov
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Nanjing Drum Tower Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07314372, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically or cytologically confirmed hepatocellular carcinoma (HCC).
Inclusion criterion 2
Child-Pugh class A or B (≤7 points).
Inclusion criterion 8
ECOG performance status 0-1.
Inclusion criterion 9
ANC ≥1.5 × 10⁹/L
Inclusion criterion 11
Platelets ≥75 × 10⁹/L
Inclusion criterion 12
Hemoglobin ≥90 g/L
Inclusion criterion 13
Total bilirubin ≤1.5 × ULN
Inclusion criterion 15
ALT and AST ≤3 × ULN
Inclusion criterion 16
Serum creatinine ≤1.5 × ULN or creatinine clearance >50 mL/min
Inclusion criterion 17
INR ≤1.2 or PT within 2 seconds above ULN
Inclusion criterion 18
At least one measurable lesion according to RECIST v1.1.
Inclusion criterion 6
Known HIV infection or other causes of immunodeficiency.
Exclusion criterion 16
Women of childbearing potential must have a negative pregnancy test; participants of reproductive potential must agree to effective contraception during treatment and for 6 months afterward.
Inclusion criterion 22
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07314372, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Adults ≥18 years of age who voluntarily agree to participate and sign informed consent.
- Histologically or cytologically confirmed hepatocellular carcinoma (HCC).
- Unresectable or not suitable for curative local therapy, or progression after prior surgery or local therapy.
- BCLC stage B or C.
- No prior systemic therapy for HCC.
- At least one measurable lesion according to RECIST v1.1.
- Availability of fresh or archival tumor tissue for FAD subtype testing; if not available at screening, MRI fat fraction may be used temporarily.
- Child-Pugh class A or B (≤7 points).
- ECOG performance status 0-1.
- Adequate organ function, including:
- ANC ≥1.5 × 10⁹/L
- Platelets ≥75 × 10⁹/L
- Hemoglobin ≥90 g/L
- Albumin ≥30 g/L
- Total bilirubin ≤1.5 × ULN
- ALT and AST ≤3 × ULN
- Serum creatinine ≤1.5 × ULN or creatinine clearance >50 mL/min
- INR ≤1.2 or PT within 2 seconds above ULN
- Urine protein <2+ or 24-hour urine protein <1.0 g
- Controlled HBV infection (HBV-DNA <2000 IU/mL; if above this level, ≥1 week of antiviral therapy with ≥1-log reduction prior to first dose). HCV-positive individuals must be managed per clinical guidelines.
- Life expectancy ≥12 weeks.
- Women of childbearing potential must have a negative pregnancy test; participants of reproductive potential must agree to effective contraception during treatment and for 6 months afterward.
Exclusion Criteria:
- Non-HCC primary liver cancers (e.g., cholangiocarcinoma, combined HCC-CCA).
- F3 subtype without liver lesions on imaging.
- Clinically significant ascites requiring therapeutic intervention, or uncontrolled pleural/pericardial effusion.
- Interstitial lung disease, pneumonitis requiring steroids, or active pulmonary infection.
- Active or history of autoimmune disease requiring systemic treatment (exceptions allowed per protocol, e.g., controlled hypothyroidism).
- Recent use (within 2 weeks) of systemic immunosuppressive therapy >10 mg/day prednisone equivalent.
- Gastrointestinal bleeding within 6 months, high-risk varices, active ulcers, fistula, perforation, or intra-abdominal abscess.
- Known bleeding or clotting disorders; therapeutic anticoagulation not permitted.
- Thromboembolic events within 6 months (e.g., stroke, PE).
- Significant cardiovascular disease, including NYHA class ≥II heart failure, recent MI (within 1 year), unstable angina, clinically significant arrhythmias, or QTc prolongation.
- Uncontrolled hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg despite treatment), or history of hypertensive crisis.
- Major vascular disease within 6 months (e.g., arterial thrombosis, aneurysm requiring repair).
- Serious non-healing wounds, active ulcers, or fractures.
- Inability to swallow oral medication or conditions affecting drug absorption.
- Severe infection within 4 weeks, therapeutic antibiotics within 14 days, fever ≥38.5°C within 7 days before enrollment, or WBC >15 × 10⁹/L.
- Known HIV infection or other causes of immunodeficiency.
- Receipt of live attenuated vaccines within 28 days before treatment.
- Any condition that, in the investigator's judgment, would interfere with study participation or interpretation of results, including substance abuse, severe psychiatric illness, or social factors.
Quoted from ClinicalTrials.gov, NCT07314372, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07314372, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.